Meta
joel topf
NephJC 2026 Fall Pledge Drive

Help keep NephJC a vital, original, and unbiased source of medical education.

NephJC 2026 Fall Pledge Drive
Background
Brian Rifkin
REFINe-ing AI’s Role in Nephrology Diagnosis

This week, we will discuss the use of LLMs for the diagnosis of complex nephrology cases. Can AI help nephrologists nail the correct diagnosis?

REFINe-ing AI’s Role in Nephrology Diagnosis
Background
Akshaya J
Too sweet to be true? Prophylactic SGLT2 ...

MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.

Too sweet to be true? Prophylactic SGLT2 inhibitors before cardiac surgery
Background
Cristina Adriana Popa
Buffering without benefit? The SODa-BIC study

This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?

Buffering without benefit? The SODa-BIC study
Background
Pallavi Prasad
Beyond Diabetic Kidney Disease: FIND-ing ...

FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.

Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role

instagram

MERCURI-2 on Instagram

MERCURI-2 on Instagram

A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Smita Divyaveer

Short video on the trial made by Smita Divyaveer and Ayushi Sharma

SODa-BIC on Instagram

SODa-BIC on Instagram

A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Daniel Ramirez and Urvashi Khan

FIND-CKD trial on Instagram

FIND-CKD on Instagram

A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Andreea Manolea

Bonus: more on finerenone in proteinuric CKD universe- visuals by Cristina Popa

TRACK trial on Instagram

TRACK trial on Instagram

A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Cristina Popa

MAJESTY trial on Instagram

MAJESTY trial on Instagram

A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Cristina Popa

NephJC on Instagram

NephJC continues to host its live journal clubs and real-time discussions on Bluesky where open dialogue, shared learning, and critical appraisal are central to what we do. For now, our scheduled chats and discussions will continue on Bluesky.

We are also expanding our presence on Instagram with a complementary goal. Instagram allows us to connect with nephrologists and the public who may not be active on X or Bluesky but who are still interested in practice-relevant research, methodology, and staying informed on ongoing NephJC activities. For many clinicians, Instagram serves as an accessible entry point rather than a space for in-depth discussion.

The NephJC editorial team recognizes that Instagram does not allow for the same type of open, back-and-forth dialogue that defines our journal clubs. We are not aiming to replicate that experience there. Instead, we see Instagram as a way to highlight important studies, share key concepts, and guide interested readers toward platforms where deeper discussion and engagement are possible.

Our commitment to thoughtful, inclusive, and rigorous discussion remains the same. Instagram is simply another way to welcome more colleagues into the NephJC community.

Follow us